search button

Therapeutic drug monitoring and tyrosine kinase inhibitors (Review)

  • Authors:
    • Pauline Herviou
    • Emilie Thivat
    • Damien Richard
    • Lucie Roche
    • Joyce Dohou
    • Mélanie Pouget
    • Alain Eschalier
    • Xavier Durando
    • Nicolas Authier

  • View Affiliations

  • Published online on: June 24, 2016     https://doi.org/10.3892/ol.2016.4780
  • Pages: 1223-1232
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The therapeutic activity of drugs can be optimized by establishing an individualized dosage, based on the measurement of the drug concentration in the serum, particularly if the drugs are characterized by an inter‑individual variation in pharmacokinetics that results in an under- or overexposure to treatment. In recent years, several tyrosine kinase inhibitors (TKIs) have been developed to block intracellular signaling pathways in tumor cells. These oral drugs are candidates for therapeutic drug monitoring (TDM) due to their high inter‑individual variability for therapeutic and toxic effects. Following a literature search on PubMed, studies on TKIs and their pharmacokinetic characteristics, plasma quantification and inter‑individual variability was studied. TDM is commonly used in various medical fields, including cardiology and psychiatry, but is not often applied in oncology. Plasma concentration monitoring has been thoroughly studied for imatinib, in order to evaluate the usefulness of TDM. The measurement of plasma concentration can be performed by various analytical techniques, with liquid chromatography-mass spectrometry being the reference method. This method is currently used to monitor the efficacy and tolerability of imatinib treatments. Although TDM is already being used for imatinib, additional studies are required in order to improve this practice with the inclusion of other TKIs.
View References

Related Articles

Journal Cover

August-2016
Volume 12 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Herviou P, Thivat E, Richard D, Roche L, Dohou J, Pouget M, Eschalier A, Durando X and Authier N: Therapeutic drug monitoring and tyrosine kinase inhibitors (Review). Oncol Lett 12: 1223-1232, 2016.
APA
Herviou, P., Thivat, E., Richard, D., Roche, L., Dohou, J., Pouget, M. ... Authier, N. (2016). Therapeutic drug monitoring and tyrosine kinase inhibitors (Review). Oncology Letters, 12, 1223-1232. https://doi.org/10.3892/ol.2016.4780
MLA
Herviou, P., Thivat, E., Richard, D., Roche, L., Dohou, J., Pouget, M., Eschalier, A., Durando, X., Authier, N."Therapeutic drug monitoring and tyrosine kinase inhibitors (Review)". Oncology Letters 12.2 (2016): 1223-1232.
Chicago
Herviou, P., Thivat, E., Richard, D., Roche, L., Dohou, J., Pouget, M., Eschalier, A., Durando, X., Authier, N."Therapeutic drug monitoring and tyrosine kinase inhibitors (Review)". Oncology Letters 12, no. 2 (2016): 1223-1232. https://doi.org/10.3892/ol.2016.4780